Christopher John Kenney
Chief Medical OfficerDr. Christopher John Kenney, also known as Chris, MD, FAAN, serves as Chief Medical Officer at Xenon Pharmaceuticals Inc. since August 2021. He serves as Chief Medical Officer of Luc Therapeutics, Inc. Dr. Kenney is a board-certified neurologist & has extensive clinic research experience within neuroscience in both industry and academic roles. He most recently served as Senior Vice President of Medical Affairs at Acorda Therapeutics and launched INBRIJA™, a novel inhaled treatment for Parkinson’s disease since 2018 until 2019 and served as its Senior Vice President of Clinical Development since 2016 until 2018. Most recently, Dr. Kenney served as Chief Medical Officer at Cadent Therapeutics, a biotech company focused on creating breakthrough therapies for neurological and psychiatric conditions, from 2019 until December 2020 when it was acquired by Novartis. Prior to that position, Dr. Kenney worked years as Vice President/Senior Vice President of clinical development at Biotie Therapies since 2013 until 2016 a biotechnology company focused on neurodegenerative and psychiatric disorders that was acquired by Acorda Therapeutics in January 2016. During that time, he led the development of a Phase II and a Phase III asset for Parkinson’s disease Dementia and motor fluctuations in Parkinson’s disease, respectively. Before joining Biotie, Dr. Kenney worked in clinical development at Novartis and Merck Serono. He serves as Chief Medical Officer at Xenon Pharmaceuticals Inc. since August 23, 2021. Dr. Kenney held faculty positions at Baylor University, from 2005 to 2007 and the University of California, San Diego, from 2003 to 2005. Dr. Kenney received his M.D. from the Boston University School of Medicine. He completed his neurology training at University of California, San Diego (UCSD) where he was Chief Resident and movement disorder fellowship training at the Baylor College of Medicine. In 2020, Dr. Kenney was appointed as a Fellow of the American Academy of Neurology. Prior to his medical training, he spent years conducting laboratory research including the development of oligonucleotides to target Interleukin-1ß and the successful cloning of human MadCAM-1. Recently, he completed the MBA program at the MIT Sloan School of Management.
公司职务
- 公司名称Xenon Pharmaceuticals Inc.股票代码XENE职务Chief Medical Officer共事同僚
- ICIan C. MortimerPresident, CEO & Director
- DADawn A. SvoronosIndependent Chairman
- TPThomas Patrick KellyChief Financial Officer
- ADAndrea DiFabioChief Legal Officer & Corporate Secretary
- DSDarren S. ClineChief Commercial Officer
- SRSteven R. GannonIndependent Director
- JDJustin D. GoverIndependent Director
- GPGary PatouIndependent Director
